Source - RNS
RNS Number : 8674G
Clinigen Group plc
01 June 2017
 

1 June 2017

 

Director's Share Dealing

 

Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Group'), the global pharmaceutical and services group, announces that it was notified on 1 June 2017 that the following transactions took place.

 

On 31 May, Debra Ainge, Chief Operating Officer, was granted share options of 2,839 ordinary shares of 0.1 pence each in the Company at a price of 634 pence per share, granted under the Clinigen Group Sharesave Plan. The options are intended to vest on 1 June 2020.

 

In addition, on 1 June, Debra Ainge exercised share options of 2,036 ordinary shares of 0.1 pence each in the Company at a price of 442 pence per share, granted under the Clinigen Group Sharesave Plan.

 

Following these transaction, Debra Ainge's total number of share options held is 42,940 and the total number of ordinary shares held is 10,254, representing approximately 0.01 per cent of the current issued share capital.

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Debra Ainge

2

Reason for the notification

a)

Position/status

Chief Operating Officer / PDMR

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Clinigen Group plc

b)

Legal Entity Identifier

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary shares of 0.1 pence each

 

 

 

GB00B89J2419

b)

Nature of the transaction

1.    The granting of 2,839 options over ordinary shares in the Company granted under the Clinigen Group Sharesave Plan.

2.    The exercise of 2,036 options over ordinary shares in the Company granted under the Clinigen Group Sharesave Plan.

c)

Currency

GBP

d)

Price(s) and volume(s)

Price(s)

Volume(s)

Grant: 634p

2,839

Exercise: 442p

2,036

 

e)

Aggregated information

- Aggregated volume

- Price

- Aggregated total

 

 

N/A

N/A

N/A

f)

Date of the transaction

Grant: 31 May 2017

Exercise: 1 June 2017

g)

Place of the transaction

London Stock Exchange, AIM

 

 

-Ends-

 

 

Contact Details

 

Clinigen Group plc

Tel: +44 (0) 1283 495 010

Shaun Chilton, Group Chief Executive Officer

Martin Abell, Group Chief Financial Officer




Numis Securities Limited

Tel: +44 (0) 20 7260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Tom Ballard (Corporate Broking)

 

 


RBC Capital Markets - Joint Broker

Tel: +44 (0) 20 7653 4000

Marcus Jackson / Elliot Thomas / Jack Wood




Instinctif Partners (media relations)

Tel: +44 (0) 20 7457 2020

Melanie Toyne-Sewell / Alex Shaw

Email: [email protected]

 

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing access to medicines. Its mission is to deliver the right medicine to the right patient at the right time.

 

The Group consists of five synergistic businesses focused in three areas of global medicine supply; clinical trial, unlicensed and licensed medicines.

 

Clinigen Clinical Trial Services is the global market leader in the management and supply of commercial medicines for clinical trials.

 

The Group is also the trusted global leader in ethically sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet need, through three of its divisions: Idis Managed Access runs early access programmes for innovative new medicines. Idis Global Access and Link Healthcare work directly with healthcare professionals to enable compliant access to unlicensed medicines on a global basis and niche essential licensed and generic medicines across Australasia, Africa and Asia (AAA region).

 

Clinigen Specialty Pharmaceuticals acquires global rights, revitalises and markets its own portfolio of niche hospital products.

 

For more information, please visit www.clinigengroup.com

 

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHLLFVIRSILIID